
Vascarta Commences Proof Of Concept Phase 1 Clinical Study Of VAS-101 In Sickle Cell Disease In The United States
(MENAFN- PR Newswire) Ten (10) patients with sickle cell disease will be treated with VAS-101 twice per week over 4 weeks for a total of 8 treatments; their blood will be drawn weekly. Five (5) patients will be treated topically on their forearm and five ( …